Introduction
Chemotherapy is the principal strategy to systemically challenge metastasized cancers. Unfortunately, metastatic prostate cancer is resistant to a broad range of antineoplastic agents [1] [2] [3] . Over the past decade new and more effective treatments have been developed based on an increased understanding of the morphological and functional characteristics of prostate cancer. Although several studies have reported favorably on response rates to chemotherapeutical regimens, results of chemotherapy in prostate cancer, single as well as multiple agent regimens, have been disappointing so far. At present, none of them have exhibited a clear advantage for survival. Importantly, involvement of the multidrug resistance (MDR) phenomenon may well play a role in progressive therapy-resistant prostate cancer and may offer an explanation for resistance to a variety of structurally and functionally distinct cytotoxic agents. Frequently, malignancies initially respond to antineoplastic treatment, but eventually relapse and become progressive despite chemotherapy. Resistance has developed, not towards the applied drug alone, but often to a variety of structurally and functionally unrelated drugs as well. The MDR phenomenon of cross-resistance to different cytotoxic agents was first described three decades ago [4] . Apart from tumors with acquired or induced MDR, malignancies can display intrinsic MDR: they are primarily unresponsive to chemotherapeutic regimens. The mechanisms of these types of resistance appear to be similar and various MDR pathways have been identified over the years. Knowledge of the biological and molecular mechanisms of MDR is increasing. This is essential for the development of new approaches to tackle the problem of chemotherapy-unresponsive tumors more successfully and find modalities by which MDR can be overcome, circumvented, or reversed. Such strategies are termed chemosensitization. In this article we will discuss the most important MDR mechanisms in relation to prostate cancer including transmembrane pumps, detoxifying pathways and changes in apoptosis. Also, we will review strategies to challenge these mechanisms, aiming at improvement of the treatment of advanced hormone-refractory prostate cancer.
MDR1 / P-glycoprotein (Pgp)
Overexpression of the MDR gene MDR1 [5] and its product P-glycoprotein (Pgp) has received a lot of attention. Pgp acts as a transmembrane efflux pump by extruding different classes of natural-product cytotoxic drugs from the cell in an energy-dependent manner. The role of Pgp-mediated multidrug resistance in prostate cancer is questionable with studies reporting conflicting results. Expression of Pgp in the human prostate cancer cell lines PC3 and DU145 has been reported [6] , albeit at low levels. Siegsmund et al. [7] found Pgp expression at low level in 8 of 11 prostate carcinoma tissues by RT-PCR. Doxorubicinresistant cell lines derived from the Dunning R3327 rat prostate carcinoma model [8] expressed Pgp as well [9] . In contrast, using Pgp-targeted immunoconjugates harboring Pseudomonas exotoxin, cell lines LNCaP and DU145 were described not to express Pgp at significant amounts [10] . Results obtained by Western blotting and immunocytochemistry appear to confirm the latter observation [11, 12] .
Chemosensitization
Modulators that are devoid of prohibitive toxicity are in clinical development [13] [14] [15] . These compounds (e.g. dexniguldipine, PAK-200, AHC-52, PSC 833, SDZ 280-446, dexverapamil) are especially selected for MDR reversal activity. They distract the drug-efflux pump, leading to decreased extrusion and increased intra-cellular accumulation of antineoplastic drugs. Efficacity and toxicity of modulators can be evaluated in xenograft-bearing mouse models of human tumors. The potential disadvantage of many chemosensitizers resides in increased toxicity as a result of higher doses of intracellular cytotoxins in normal tissue or cells. Myelotoxicity has often been and remains the dose-limiting factor in chemotherapy. Strategies for preventing bone marrow toxicity have therefore become a high priority of research on dose escalation protocols. A promising approach was the construction of transgenic mice [16] . Constructs of cDNA encoding full-length human MDR1 in a plasmid carrier were injected into mouse embryos. A homozygous line was obtained in which the expression of the MDR1 gene was limited to the bone marrow and the spleen [17] . The level of MDR1 expression in bone marrow cells was clinically significant and comparable with that seen in an in vitro selected cell line (KB-8-5) that exhibits 3-to 18-fold resistance, depending on the drug. Expression of Pgp was of particular significance, because the MDR1-expressing bone marrow was protected against chemotherapy-induced toxicity in comparison to normal bone marrow. This protective advantage of the MDR1 gene could be transferred to recipient animals by bone marrow transplantation. Subsequently, protection of bone marrow cells by virtue of expression of the drug resistance gene MDR1 was also clinically investigated using a gene therapeutic approach [18] . Due to technical limitations at the gene transduction level, no significant dose escalation of chemotherapy in patients could be detected. Other strategies to overcome MDR1-related resistance are liposomal encapsulation of cytotoxic drugs [19] , the use of Pgp as target for immunotherapy by monoclonal antibodies [20] , and selectively killing cells that express Pgp on their surfaces using protein toxins, such as Pseudomonas exotoxin, that are chemically linked or recombinantly attached to certain antiPgp antibodies, such as MRK16 [21] . Recently Ihnat et al. [22] reported that application of sub-toxic doses of DNA crosslinking agents could be used to modulate multidrug resistance through suppression of Pgp, prior to treatment with a second cytotoxic agent. These findings should be further explored in vivo. Several studies were performed aiming at chemosensitization of MDR1-driven MDR of prostate cancer. Rat mdr1b mRNA was found in hormone-insensitive sublines of Dunning rat prostate carcinoma cells. Reversal of resistance against vinblastine and paclitaxel was achieved with verapamil [23] . Ketoconazole has been described as MDR reversing agent in prostate cancer [7] . This antifungal imidazole has been demonstrated to repress steroid synthesis, to have direct cytotoxic effect on tumor cells and to potentiate the efficiency of chemotherapeutic drugs as it blocks Pgp. Experiments in a three-dimensional in vitro model for prostate cancer revealed resistance against doxorubicin, expression of Pgp and modulation of resistance with MDR1 modulators [24] . Downregulation of Pgp by reactive oxygen species in multicellular prostate tumor spheroids was observed [25] . In summary, clinical relevance of MDR1 expression in prostate cancer remains questionable and chemosensitization approaches in experimental and clinical prostate cancer models have to be further investigated for a potential benefit for prostate cancer patients.
Multidrug Resistance-Associated Protein (MRP)
The role of the multidrug resistance-associated protein (MRP) in MDR of prostate cancer is the subject of recent and current investigations. In 1992 MRP [26] was found to mediate drug resistance in distinct MDR tumor cell lines lacking Pgp. Since then 5 more members of the MRP family have been described [27] . MRP1-3 transport MDR drugs at varying degree and are active as carriers for transport of glutathione S-conjugated endoand xeno-biotics [28] . The role of MRP4-6 as MDR transporter remains a subject of investigation. MRP1 expression is found in all major organs analyzed, including prostate and all cell types from peripheral blood [29] . MRP1 is a Mr. 190,000 protein that is encoded by the MRP1 gene, which is located on chromosome 16p 13 [26] . In prostate cancer, MRP1 is expressed even in early stages [30] . MRP1 expression increases in late disease stages [12] and is consistently present in all prostate cancer cell lines examined [11] . MRP2 expression has been found in prostate cancer cell lines and xenografts (van Brussel, unpublished results), MRP3 in prostate cancer cell lines [31] , and MRP4 in prostate cancer [32] . MRP5 and MRP6 expression in prostate cancer has not been reported thus far.
Chemosensitization
Compounds with proven MRP1-associated MDR-modulating capacity are rare at present. Some agents, however, which originally were found to circumvent Pgp-mediated MDR effectively show some activity, such as verapamil [33] , its Lstereoisomer [34] , cyclosporin A and its non-immunosuppressive derivative SDZ PSC 833 [33] , and dihydropiridines [35] . In addition, depletion of glutathione via the glutathione synthesis inhibitor D,L-buthionine-(S,R)-sulfoximine (BSO) [36] , was successful in modulating MRP1-related MDR. Circumvention of MRP1-related MDR was achieved in etoposide-resistant prostate cancer cell lines by the dihydopyridine derivative NIK250 [37] . Particular attention is paid to the effective inhibition of MRP1 induced by the leukotriene D4 receptor antagonist MK-571 [38] , a specific MRP1 blocker. MK-571 is clinically used for relieving bronchoconstriction in asthma patients [39] , and can be safely administered in high doses [40] either intravenously or orally. Quite recently a similar leukotriene D4 receptor antagonist (ONO-1078) was also described to circumvent MRP1-modulated MDR in cancer cell lines [41] . Zafirlukast, another leukotriene inhibitor, was demonstrated to have MDR modulation potential in prostate cancer cell lines (van Brussel, unpublished results). The compounds MK-571, ONO-1078, and zafirlukast would bind to leukotriene C4 and D4 receptors, thus interfering with the MRP1-driven efflux of leukotrienes [42] . Functional testing by visualization of MRP1-mediated efflux via specific fluorescent substances with and without the MRP1 modulator MK-571 has also been achieved in acute myeloid leukemia blasts from patients and in several AML cell lines [43] . MRP1 activity was a prognostic factor for achievement of complete remissions suggesting that MRP1 contributes significantly to drug resistance in AML. In prostate cancer, a functional role for the members of the MRP family in prostate cancer is subject of current investigations. To elucidate the role of MRP1 in the resistance of prostate cancer against chemotherapy, multidrug resistant in vitro prostate cancer models were developed from the human prostate cancer cell lines PC3 and DU145 (van Brussel, unpublished results). Increased expression of MRP1 in multidrug resistant prostate cancer cells is functionally related to resistance against chemotherapy. Effective blocking of MRP1 pump function by leukotriene receptor antagonists, such as MK-571 and zafirlukast, resulted in the intracellular accumulation of MRP1 substrate and increased sensitivity to cytotoxic drugs. This provides some evidence for a functional role of MRP1 in drug resistance of prostate cancer, however, results have to be interpreted cautiously. MRP homologs other than MRP1 and other MDR mechanisms may well be involved in the MDR phenotype of prostate cancer cells. Studies on functional involvement of MRP2-6 in prostate cancer will be initiated. Furthermore, the role of MRP1 in clinical prostate cancer requires further study. Also, approaches to clinically inhibit MRP1 must be carefully designed, because MRP1 is ubiquitously expressed [27] . Fine-tuning of dosages, schedules of chemotherapy, and reversal agents is necessary to limit toxicity. For instance, possible myelotoxicity may be reduced by chemoprotection of the bone marrow, achieved with retrovirus-mediated gene transfer of MRP cDNA [44] . Clinically, Onkologie 2003;26:175-181 establisment of the role of MRP in multidrug resistant prostate cancer would offer a potential to apply MRP modulators in combination with chemotherapeutic regimens to treat patients with advanced hormone-refractory prostate cancer.
Glutathione
Several studies have demonstrated that glutathione is an important factor in the sensitivity of cancer cells to cytotoxic drugs. Glutathione and glutathione-S-transferase detoxification systems protect cancer cells against the lethal effects of chemotherapy. Changes in the anticancer drug detoxifying anti-oxidant glutathione metabolism [45] and in expression or activity of glutathione-S-transferase intracellular transport proteins (GST) have been described in relation to MDR. GSTs catalyze the conjugation of hydrophobic, electrophilic xenobiotics by glutathione, resulting in conjugated or transformed metabolites that are more easily excretable and less toxic. Some GST isozymes may participate in the repair of oxidative damage to membrane lipids and DNA. Furthermore, GSTs are high-capacity intracellular binding proteins which may serve in storage, transport, or sequestration of many hydrophobic compounds. The relation to MRP has been extensively reported [46] . These properties suggest that GSTs may function as important cellular defenses against the cytotoxic effects of antineoplastic agents. Interestingly, expression of GST-π, a detoxifying enzyme and part of the glutathione detoxifying pathway, is significantly increased in advanced hormone-independent prostate cancer [12] . Expression of GST-π in advanced clinical prostate cancer is a novel finding. Previous studies have only reported the lack of its expression in locally confined prostate cancer obtained from radical prostatectomy samples [30, 47] and suggested a role of GST-π inactivation in the early steps of prostatic carcinogenesis [48] . Accordingly, in our series of tumors locally confined prostatic carcinomas were entirely GST-π-negative, whereas the disseminated cancers clearly expressed GST-π, especially in hormone-independent progressive disease [12] . Concomitant overexpression of MRP and GST-π may synergistically result in increased drug resistance of advanced prostate cancer. Another study reports expression of drug-metabolizing enzymes of the cytochrome P450 subfamilies CYP1A, CYP2C, CYP3A, GST-α and GST-µ [49] in prostate cancer.
Chemosensitization
In prostate cancer reversal of MDR by challenging the glutathione pathway has been successfully performed in vitro in only few studies. Ripple et al. [50] reported reversal of melphalan resistance of MDR LNCaP sublines by depletion of glutathione with BSO. Our group demonstrated chemosensitization of MDR PC3 and DU145 derivatives with a similar approach (van Brussel, unpublished results). Further in vivo and eventually clinical studies are warranted to clarify the importance of glutathione-aimed strategies in prostate cancer. A putative role for the glutathione metabolism in prostate cancer is of importance, especially in the context of MRP-expressing prostate cancer. Chemosensitization strategies combining GSH depletion and MRP blocking are the subject of current investigations and may ameliorate the results of chemotherapy in clinical prostate cancer.
Apoptosis
The phenomenon of apoptosis, also called programmed cell death, has received a great deal of attention. It is widely appreciated that changes in the regulatory processes of apoptosis contribute to the malignant phenotype of cancer cells. Importantly, as many cytotoxic agents act through induction of apoptosis, alterations in apoptotic processes contribute to the multidrug resistant phenotype of malignancies [51] . Bcl-2, which has been identified as a powerful inhibitor of apoptotic cell death, appears to be expressed at low levels in low-grade prostate carcinoma and at higher levels in high-grade tumors [52] . Accordingly, Bcl-2 expression was increased in clinical hormone-independent prostate cancers as compared to organconfined cancers [12] . Bcl-2 expression in prostate cancer has previously been related to the androgen-independent phenotype [53] . Relatively high Bcl-2 levels may promote cell survival and protect androgen-independent prostate cancer cells from drug-induced apoptosis [54] . Bax, a pro-apoptotic protein, has been found to be well expressed in prostate cancer [52] . In a study on clinical prostate cancer Bax is equally and homogeneously expressed in normal prostate and prostate cancer cells in all phases of progression [12] . Mutation of the p53 gene is the most common molecular alteration in cancers resulting in decreased apoptosis and possibly resistance to apoptosis-inducing cytotoxic agents [55] . Correlation between p53 mutations and tumor progression has been presented in several studies, with mutations occurring as a late event in the development of prostate cancer [56] . This is in concordance with our finding of more frequently occurring p53 expression in advanced disease [12] , which may explain the decreased susceptibility to apoptosis-inducing agents. We observed a significantly increased number of p53-positive patients in hormone-independent cancers. Also, p53 expression was statistically significantly related to a higher histological grade. These findings should be interpreted cautiously as immunohistochemical expression of p53 does not necessarily represent p53 mutation [57] . Interestingly, transfection of a temperature sensitive p53 mutant into the LNCaP human prostate cancer cells produced a time-dependent increase in MRP1. Mutant p53 and increased MRP1 were related to drug accumulation and decreased drug sensitivity [58] . Apart from Bcl-2 and p53, several other molecular alterations have been documented in prostate cancer, as reviewed by Bruckheimer [59] , involving the androgen receptor and cell-cycle regulatory genes such as the retinoblastoma suppressor gene, c-myc, and p21. Ras gene family mutations may contribute to the pathogenesis of prostate cancer. Loss of heterozygosity and alterations in newly identified tumor suppressor genes such as PTEN/ MMAC1 may influence apoptosis in prostate cancer. The importance of these genetic changes for MDR of prostate cancer remains to be determined. Another important factor in the apoptotic chain is Fas, a member of the nerve growth factor / tumor necrosis factor receptor superfamily. It is present in benign and malignant prostate cells [60] and induces cell death. Disruption of the Fas/Fas ligand signaling pathway may result in acquired MDR [60] . Activation of protein kinase C (PKC) induces apoptosis in prostate cancer cells [61] and therefore pharmacological manipulation of PKC may be of interest in MDR prostate cancer.
Chemosensitization
Countering of Bcl-2 related MDR may become applicable in the future possibly by the development of small-molecule pharmaceuticals that can disrupt Bcl-2/Bax interactions and thus abrogate Bcl-2 protein function [62] . Sequence-specific down-regulation of Bcl-2 expression has been reported in vitro in lymphoma cell lines and AML cells using synthetic antisense oligonucleotides, showing that decreased expression of the Bcl-2 protein can result in markedly enhanced sensitivity to chemotherapeutic drugs [63] . Antisense approaches to down-regulation of Bcl-2 function in prostate cancer are feasible. Reduction in Bcl-2 protein levels in LNCaP cells by Bcl-2 antisense oligonucleotides resulted in enhanced sensitivity to the cytotoxic drug etoposide [64] . Another study treated Shionogi tumor cells with antisense Bcl-2 oligonucleotides resulting in downregulation of Bcl-2 expression and chemosensitization to taxanes in this model for androgen-independent prostate cancer [65] . These findings demonstrate that agents that diminish Bcl-2 levels could possibly be used as chemosensitizers in the treatment of prostate cancer. Alternatively, it has been observed that certain lymphokines and retinoids can regulate the expression of the Bcl-2 gene and sensitize to antineoplastic drugs (reviewed by Reed [66] ), rendering cancer cells more prone to induction of apoptosis by chemotherapeutic drugs. Paclitaxel, vinblastine, and docetaxel induce Bcl-2 phosphorylation-associated apoptosis in Bcl-2 expressing PC3 prostate cancer cells [67] . Other chemotherapeutic agents, such as mitomycin, actinomycin D, doxorubicin, and etoposide do not induce Bcl-2 phosphorylation [68] . The combination of 13-cis-retinoic acid (CRA) and interferon-α (IFN-α) is cytotoxic in tumor cells that overexpress Bcl-2 and reduces the expression of Bcl-2, overcoming Bcl-2-mediated resistance [69] . Clinical studies on this regimen combined with taxanes are currently underway [70] . Bax, Akt/P13K, BH3 peptides, Fas, NF-κB are targets in the apoptotic pathway that are under investigation [71] . With increased knowledge of apoptosis at the molecular level, it may be possible to develop novel approaches for cancer therapy that specifically aim at modulating the physiologic programmed cell death pathway. Apoptosis is likely to play an important role in prostate cancer and the development of apoptosis-stimulating techniques may be of particular importance for the treatment of advanced prostate cancer.
Conclusion
Metastatic hormone-independent prostate cancer remains a major oncological challenge. However, basic and clinical research have provided insight into underlying mechanisms of drug resistance and further study of possibilities to circumvent this resistance, innovative use of established drugs and development of more potent antineoplastic agents will remain of the utmost importance. Modulation of MDR in prostate cancer is the subject of current studies and promising results were obtained in vitro and in vivo. Clinical relevance of modulation strategies are and will be the subject of investigation. Attempts at challenging progressive hormone-independent prostate cancer more successfully are still experimental and should be carried out within the setting of controlled clinical studies.
